Roche's (RHHBY_) blockbuster cancer drug Herceptin works similarly, except it's not a vaccine but an antibody that attaches to HER2 receptors on breast cancer cells. In order for Herceptin to be effective, however, the breast cancer cells must overexpress HER2, meaning the cells need to have large numbers of HER2 receptors on their surface.
out rest for 17.90 Re: out half 16.90 keep rest for 18 if 17 breakRe: almost there from 16 alert Re...
Msg #1056 Thread #673662154 (Rec: 0)
13.2M shares short, longs don't need to do anything, just sit back and enjoy the ride back to $30
Neratinib for Breast Cancer Brain Metastases ($PBYI). ... nice if they were to announce movement into Phase 3 of their breast cancer drug under development where as Celldex Improves Survival in Brain Cancer Patients. Important Articles (CLDX). Celldex Therapeutics ... It is currently in a phase 3 trial for the treatment of Glioblastoma Multiforme (brain cancer). ....
CLDX is going to be the next ITMN new updated video
glioblastoma – the most aggressive form of brain cancer. Act IV: A Phase 3 Trial for Newly Diagnosed EGFRv3-positive. Glioblastoma ReACT:
See our latest projects
There’s always something new happening at Celldex! Come check out our latest activities.
Side Effect Profiles of Immune Checkpoint Therapeutics – Parts 2 and 3 - Merck pembrolizumab
June 30, 2014
We will discuss alternative approaches next time, but first there is some new data on novel immune checkpoint therapies to consider. These are the TNF receptor superfamily proteins that we discussed last month (link): 4-1BB, CD27, OX40 and GITR. There is admittedly very little data to date. Pfizer’s (PFE) anti-4-1BB antibody PF-05082566 reached a safe dose in Phase 1 without undue toxicity signals (ASCO 2014, Abstract #3007). Pfizer disclosed combination trials with rituximab in Non-Hodgkin Lymphoma (NHL) and pembrolizumab (anti-PD-1). The BMY antibody urelumab was tolerated through its’ dose escalation cohorts, and ex vivo analysis showed activation of CD8+ T cells and NK cells (ASCO 2014, Abstract #3017). The Celldex anti-CD27 mAb also has demonstrated safe dose escalation, although to date without signs of clinical activity (ASCO 2014, Abstracts #3024 and #3027). Celldex (CLDX) claims planned studies in combination with nivolumab, ipilimumab, and the targeted therapeutics darafenib and trametinib.
As we discussed in an earlier post, 4-1BB, CD27, OX40 and GITR are evolutionarily closely related receptors. Biomarker studies such as the one performed in the urelumab trial will be essential in understanding how these immune stimulatory pathways will differentiate clinically and which will be safe in combination settings.
Bristol Mayer Squibb (BMY) has paid Celldex $5 million up front and will pay half of development costs for a new study that teams Bristol's PD-1 drug nivolumab up with Celldex's promising varlilumab against solid tumor cancer.
A spokeswoman for the FDA said the agency cannot discuss the status of applications.
Merck is first seeking to sell its PD-1 drug for patients whose skin cancer does not respond to treatment with Yervoy, a Bristol-Myers immunotherapy that targets a different part of the immune system.
"In oncology, combinations typically provide superior benefit," Roger Perlmutter, head of research at Merck, said in a June interview. "But picking them is tricky. We first need to understand it as monotherapy."
Roche's Avastin, Rituxan, and Herceptin account for nearly 40% of the company's $52 billion in annual sales. Rituxan and Avastin both face generic drug risk, while Herceptin faces new and upcoming drugs such as Puma Biotechnology's neratinib that with Roche being the world leader in cancer drugs, Celldex makes sense as an acquisition or partnership target.
I liked the Motely Fools writers this comment on 6th December 2013 - for PUMA it was 100% true......Roche's Avastin, Rituxan, and Herceptin account for nearly 40% of the company's $52 billion in annual sales. Rituxan and Avastin both face generic drug risk, while Herceptin faces new and upcoming drugs such as Puma Biotechnology's neratinib that are simply more effective. With Roche being the world leader in cancer drugs, Celldex makes sense as an acquisition or partnership target.
Amgen (NASDAQ: AMGN ) , Roche (NASDAQOTH: RHHBY ) , and even Alexion might still aggressively seek Celldex in the future.
Amgen recently acquired Onyx for more than $9 billion. Prior to the acquisition, Amgen's growth prospects were dim as the majority of its pipeline was in early stages. Onyx's pipeline is fully developed, however, with three marketed products in oncology. Celldex would give Amgen a clinical pipeline worth billions if successful